These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31406254)

  • 21. Genomic Profiling Identifies Association of
    Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
    Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
    Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
    Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
    Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
    J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
    Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
    Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
    Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
    Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
    Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
    J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.
    Nakagawa M; Yamaguchi M; Endo M; Machida Y; Hattori A; Tanzawa F; Tsutsumi S; Kitabayashi I; Kawai A; Nakatani F
    J Bone Oncol; 2022 Jun; 34():100430. PubMed ID: 35493690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct IDH1/2-associated Methylation Profile and Enrichment of
    Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
    Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
    Fujiwara H; Tateishi K; Misumi K; Hayashi A; Igarashi K; Kato H; Nakatsuka T; Suzuki N; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Kogure H; Nakai Y; Isayama H; Hasegawa K; Fukayama M; Soga T; Koike K
    Sci Rep; 2019 Dec; 9(1):18859. PubMed ID: 31827136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
    Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A; Menendez JA
    Carcinogenesis; 2019 Mar; 40(1):27-40. PubMed ID: 30428017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
    Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
    Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
    Guilhamon P; Eskandarpour M; Halai D; Wilson GA; Feber A; Teschendorff AE; Gomez V; Hergovich A; Tirabosco R; Fernanda Amary M; Baumhoer D; Jundt G; Ross MT; Flanagan AM; Beck S
    Nat Commun; 2013; 4():2166. PubMed ID: 23863747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
    Vuong HG; Ngo TNM; Dunn IF
    Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
    Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
    Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Yun H; Görlich K; Wichmann M; Schwarzer A; Preller M; Thol F; Meyer J; Haemmerle R; Struys EA; Jansen EE; Modlich U; Li Z; Sly LM; Geffers R; Lindner R; Manstein DJ; Lehmann U; Krauter J; Ganser A; Heuser M
    Blood; 2013 Oct; 122(16):2877-87. PubMed ID: 23954893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.